Topics

Hoth Therapeutics completes phase 1 of in-life dose escalation study for treating Eczema

07:25 EDT 9 Oct 2019 | Pharmaceutical Business Review

The clinical study was conducted by an independent third party, monitoring the tolerance and toxicity of its proprietary BioLexa Platform on minipigs. There were two phases with the

The post Hoth Therapeutics completes phase 1 of in-life dose escalation study for treating Eczema appeared first on Pharmaceutical Business review.

Original Article: Hoth Therapeutics completes phase 1 of in-life dose escalation study for treating Eczema

NEXT ARTICLE

More From BioPortfolio on "Hoth Therapeutics completes phase 1 of in-life dose escalation study for treating Eczema"

Quick Search